The GLP-1 Research Landscape: From Gut Hormone to Multi-Agonist

The GLP-1 research field traces back to a fairly narrow physiological observation: glucose taken orally provokes a larger insulin response than the same amount of glucose delivered intravenously. That gap implied the gut was releasing something into the bloodstream in response to food — a class of signals researchers named “incretins.” Glucagon-like peptide-1 (GLP-1) turned out to be one of the two major incretin hormones, secreted by intestinal L-cells in response to nutrient intake.

From incretin biology to receptor agonists

Native GLP-1 has a problem for therapeutic and research use: it’s degraded by the enzyme DPP-4 within minutes of release, giving it an extremely short half-life. Much of the subsequent research effort went into designing GLP-1 receptor agonists — molecules that activate the same receptor but resist DPP-4 degradation, extending activity from minutes to hours or, with further modification, days.

This is the lineage that produced semaglutide: a GLP-1 analog modified with amino acid substitutions and a fatty acid side chain (via a technique called acylation) that both resists enzymatic breakdown and binds reversibly to albumin in the bloodstream, extending its half-life to roughly a week. That pharmacokinetic profile is what enabled once-weekly dosing protocols, a significant departure from earlier short-acting incretin-based compounds.

Beyond single-target: multi-agonist design

The more recent direction in this research area is multi-agonism — designing a single molecule that activates more than one receptor pathway simultaneously, based on the observation that combining mechanisms tends to produce larger metabolic effects than any single pathway alone.

• GLP-1/GIP dual agonists combine GLP-1 receptor activity with activation of GIP (glucose-dependent insulinotropic polypeptide), the second major incretin hormone. GIP’s role is more complex and was historically debated, but dual-agonist research has shown that combining the two pathways produces effects that exceed GLP-1 activation alone.
• GLP-1/GIP/glucagon triple agonists, such as retatrutide, add a third pathway — glucagon receptor activity — which in isolation increases energy expenditure but also raises blood glucose; the engineering challenge is balancing that against the glucose-lowering effects of the GLP-1 and GIP components in the same molecule.
• Amylin analogs, such as cagrilintide, work through a mechanistically distinct pathway — amylin is co-secreted with insulin by pancreatic beta cells and acts on appetite regulation and gastric emptying through amylin receptors rather than the GLP-1 receptor. This is why cagrilintide is often studied in combination with a GLP-1 agonist (as in cagrilintide/semaglutide co-formulations) rather than as a substitute for one — the two pathways are complementary rather than overlapping.

Why mechanism matters for research design

Because these compounds act through different receptor combinations, they aren’t interchangeable variables in a study — a triple agonist and a single GLP-1 agonist are not simply “stronger” and “weaker” versions of the same intervention; they engage different physiological systems with different downstream effects and different considerations for experimental design. Understanding which receptors a given compound activates is the starting point for predicting what a study is actually measuring.

The current state of the field

Multi-agonist design remains an active area of pharmacological research, with ongoing work characterizing the relative contribution of each receptor pathway, optimal ratios of activity across targets, and longer-term metabolic effects. The field has moved fast — from a single-hormone incretin observation to engineered multi-receptor molecules — in a relatively short span, and the mechanistic questions (rather than the compounds themselves) are what continue to drive the next generation of research design.

For specific compound data — molecular weight, sequence information, and mechanism-of-action detail — see the individual product pages in the full catalog.